S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:PALI

Palisade Bio (PALI) Stock Price, News & Analysis

$0.40
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.39
$0.42
50-Day Range
$0.36
$0.96
52-Week Range
$0.36
$3.65
Volume
131,322 shs
Average Volume
173,688 shs
Market Capitalization
$3.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75

Palisade Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,092.4% Upside
$8.75 Price Target
Short Interest
Healthy
0.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.20mentions of Palisade Bio in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$6,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.38 out of 5 stars

PALI stock logo

About Palisade Bio Stock (NASDAQ:PALI)

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

PALI Stock Price History

PALI Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Palisade Bio Shares Drop 23% After Warrants Exercised
Why Is Palisade Bio (PALI) Stock Up 100% Today?
Stocks to Watch: Palisade Bio
Palisade Bio files to sell its shares
See More Headlines
Receive PALI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
3/29/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PALI
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.75
High Stock Price Target
$16.00
Low Stock Price Target
$1.50
Potential Upside/Downside
+2,092.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,260,000.00
Pretax Margin
-4,920.00%

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$4.24 per share

Miscellaneous

Free Float
9,063,000
Market Cap
$3.70 million
Optionable
Not Optionable
Beta
1.33
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

PALI Stock Analysis - Frequently Asked Questions

Should I buy or sell Palisade Bio stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PALI shares.
View PALI analyst ratings
or view top-rated stocks.

What is Palisade Bio's stock price target for 2024?

1 Wall Street analysts have issued 1-year price objectives for Palisade Bio's stock. Their PALI share price targets range from $1.50 to $16.00. On average, they predict the company's stock price to reach $8.75 in the next twelve months. This suggests a possible upside of 2,092.4% from the stock's current price.
View analysts price targets for PALI
or view top-rated stocks among Wall Street analysts.

How have PALI shares performed in 2024?

Palisade Bio's stock was trading at $0.59 on January 1st, 2024. Since then, PALI shares have decreased by 32.4% and is now trading at $0.3991.
View the best growth stocks for 2024 here
.

Are investors shorting Palisade Bio?

Palisade Bio saw a drop in short interest in March. As of March 15th, there was short interest totaling 45,200 shares, a drop of 41.1% from the February 29th total of 76,800 shares. Based on an average daily volume of 2,610,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.5% of the shares of the stock are sold short.
View Palisade Bio's Short Interest
.

When is Palisade Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our PALI earnings forecast
.

How were Palisade Bio's earnings last quarter?

Palisade Bio, Inc. (NASDAQ:PALI) released its earnings results on Thursday, November, 9th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.09.

Who are Palisade Bio's major shareholders?

Palisade Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.56%). Insiders that own company stock include Donald Allen Williams, John David Finley, Michael John Dawson, Robert J Trenschel, Robert J Trenschel and Thomas Hallam.
View institutional ownership trends
.

How do I buy shares of Palisade Bio?

Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PALI) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners